Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B), while State Street SPDR S&P Homebuilders ETF trades at $94.93 (market cap $1.49B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 4.1× State Street SPDR S&P Homebuilders ETF's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| IOVA | XHB | |
|---|---|---|
Market Cap | $6.04B | $1.49B |
Volume | 14,805,993 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $14.82 | $121.36 |
52-Week Low | $1.81 | $94.86 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.65, down 0.25% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but potential tailwinds from new housing affordability legislation and institutional interest.
The outlook for XHB is mixed, balancing sector-specific risks like rising rates against legislative support and valuation opportunities. Investment appeal hinges on a housing market recovery, with risks including economic sensitivity and inventory constraints. Sentiment is cautious but notes historical buying signals at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
